Infinity Bio Secures $8M Series A to Revolutionize Immune Profiling with Next-Gen Antibody Insights

Infinity Bio, Inc. is thrilled to announce a major funding milestone with a successful raise of $8,000,000. This significant investment will empower the company to further its revolutionary work in providing detailed insights into the immune system through its proprietary antibody profiling platform. At the heart of Infinity Bio’s innovative approach is its comprehensive measurement of the antibody reactome, which reveals the specific targets of individual immune responses to all known human viruses, human proteins (autoimmunity), and allergen proteins. Developed in Ben Larman's Lab of Precision Immunology at Johns Hopkins University, the company's flagship MIPSA assay is built on decades of foundational research in genomics, proteomics, immunology, and bioinformatics. The freshly injected capital will be strategically deployed to optimize and expand the capabilities of the MIPSA assay, ensuring best-in-class turnaround times and cost-efficiency. This funding round marks another step forward in Infinity Bio’s mission to transform both research and clinical diagnostics. The company is poised to make a significant impact by enabling researchers, clinicians, and customers globally to gain unprecedented insights into immune function and dysfunction. With a team of experienced professionals and access to state-of-the-art facilities, Infinity Bio is set to drive innovation within the field of precision immunology and beyond. The company plans to channel these funds into further research and development, scaling operations, and strengthening collaborations with leading institutions. Overall, this investment not only validates the robust science underpinning Infinity Bio’s platform but also highlights the growing recognition of the transformative potential of antibody profiling technologies in healthcare and biomedical research.